Industry Analysis - Changing Dynamics in Worldwide Psychiatric FranchisesDecision ResourcesDecember 15, 2006 18 Pages - SKU: DECR1399786 |
| Countries covered: Global Introduction The treatment of psychiatric diseases is hardly straightforward; patients often try many different drug regimens and combinations in order to identify an optimal course of therapy. Although the long-term goal in treating psychiatric diseases is to halt disease progression and to prevent the onset of permanent damage, a more attainable step will be to individualize treatment for patients using available drugs. Get the Answers You Need to Shape Your Strategy Psychiatric franchises are transforming as industry players concede potential opportunities to others, capitalize on available opportunities, or challenge others for coveted opportunities. What are the major psychiatric franchises? What characteristics of the psychiatric industry make for a dynamic market? Few innovative psychiatric drugs are in development; however, psychiatric disease markets are substantial. Yet, big pharma's single-minded focus on developing the next blockbuster drug concedes a large portion of pharmaceutical drug markets to midsize pharma companies. Which midsize companies have the largest psychiatric franchises, and how are they fi lling the market space conceded by big pharma? Identifying the genetic variations associated with psychiatric diseases will be essential in the development of drugs that provide personalized treatment options for patients. What pharmacogenomics-based agents are currently in development? Scope
|
Additional Information
Mentioned in This Report—Companies
- Abbott Laboratories
- Affymetrix
- Albany Molecular Research
- Alza
- Amgen
- AstraZeneca
- Bristol-Myers Squibb
- Carlsson Research
- Clinical Data
- Dr. Reddy’s Laboratories
- Eisai
- Eli Lilly
- Forest
- GlaxoSmithKline
- Ivax
- Johnson & Johnson
- Lundbeck
- Memory Pharmaceuticals
- Merck KGaA
- Mylan
- NeuroSearch
- Novartis
- Organon
- Otsuka
- Perlegen Sciences
- Pfi zer
- PGxHealth
- Reckitt Benckiser
- Sandoz
- Sanofi -Aventis
- Servier
- Shire Pharmaceuticals
- Solvay
- Targacept
- Teva Pharmaceuticals
- UCB
- Vanda Pharmaceuticals
- Verispan
- Vintage Pharmaceuticals
- Watson Pharmaceuticals
- Wyeth Pharmaceuticals
More Global Prescription Drugs Reports
Global Pharmaceuticals & Medicine Manufacturing by
IBISWorld
Global Pharmaceuticals & Medicine Manufacturing This industry comprises companies that manufacture biological, medicinal and pharmaceutical products in various forms including ampoules, tablets, capsules, vials, ointments, powders, ...
Ophthalmic Drugs: World Market Prospects 2012-2022 by
Visiongain
How to find trends and revenue predictions for the ophthalmic drug industry
What are the commercial prospects for treating eye disorders? Visiongain's report shows you ...
Global Pharmaceutical Survey 2012–2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry by
iCD Research
Synopsis
This report is the result of an extensive survey drawn from ICD Research’s exclusive panel of leading pharmaceutical industry executives. The opinions and ...
Global Pharmaceutical Survey 2012–2013: Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry by
iCD Research
Synopsis
This report is the result of an extensive survey drawn from ICD Research’s exclusive panel of leading pharmaceutical industry executives. The opinions and ...
World Market for Prescription Dermatological Drugs, 8th Edition (Antiacne, Antiaging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer, Melasma and Seborrhea Treatments) by
Kalorama Information
This Kalorama Information report, The Worldwide Market for Prescription Dermatological Drugs represents the eighth time that Kalorama has detailed the various categories of prescription dermatological ...
See all reports like this >>
Related Markets
Prescription Drugs Reports
- Rx-to-OTC Switching Strategies - New Switching Opportunities in Weight Management and Smoking Cessation, but Encouraging the Uptake of Self-Medication Remains a Challenge
- Antivirals Market to 2017 - Increased Uptake of High Priced Combination Drugs will Offset the Impact of Generics in the HIV Therapeutics Market
- Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs Through the DLO’s Seven Nosologies Program
- Chinese Markets for Hepatitis Drugs
- Anti-Hypertensives Market to 2017 - Patent Expiries of Blockbusters such as Diovan, Micardis, Avapro and Atacand to Accelerate Erosion
